Multiple Myeloma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Multiple Myeloma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
14.5% (16/110) of MM BM samples showed dysregulated FGFR3 expression.
|
12028033 |
2002 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutation analysis revealed no mutations in the presenting myeloma or MGUS samples.
|
12139740 |
2002 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR3 is thus a plausible candidate for targeted therapy in a subset of MM patients.
|
15029211 |
2004 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
|
19594619 |
2009 |
Multiple Myeloma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.
|
24466111 |
2014 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
|
27509849 |
2016 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
|
12433679 |
2003 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
|
12433679 |
2003 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A t(4;14)/IGH-FGFR3 was detected in 28 PCM (11.1%) and 5 MGUS (1.9%; P < 0.001).
|
21156229 |
2010 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Although extensively studied in plasma cell neoplasms, there is little information in the literature regarding FGFR3 expression in malignant lymphomas, and it is unclear whether lymphoma patients may also benefit from anti-FGFR3 therapy.
|
18528286 |
2008 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among recurrent IGH translocations in MM, the frequency of t(4;14) (IGH and FGFR3) or t(11;14) (IGH and CCND1) is greater than the frequency of t(14;16) (IGH and MAF).
|
23460268 |
2013 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
|
19381019 |
2009 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Approximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3).
|
25402977 |
2015 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
As a part of these translational efforts, novel drugs that inhibit oncogenic proteins overexpressed in defined molecular subgroups of the disease, such as FGFR3 and MMSET in t(4;14) MM, are currently being developed.
|
23233602 |
2012 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
As the expression of FGFR3 is undetectable in 30% of the t(4;14)+ MM patients, MMSET has been suggested to play an important role in the malignant transformation associated with the t(4;14) translocation.
|
16115125 |
2005 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
|
19147757 |
2009 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in multiple myeloma and peripheral T-cell lymphoma.
|
23696246 |
2014 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Expression of fibroblast growth factor receptor 3 (FGFR3), presumptively dysregulated on der(14), was detected by RT-PCR in only 23 of 31 (74%) patients with t(4;14)(+) MM.
|
12393535 |
2003 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074.
|
14715624 |
2004 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Findings from multiple myeloma (MM) indicate that FGFR3 also can act as an oncogene, and mutation of codon 249 in the fibroblast growth factor receptor 3 (FGFR3) gene was recently detected in 3/12 primary cervical carcinomas.
|
11904459 |
2001 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Frequent FGFR3 kinase activating mutations in MM with t(4;14) translocations substantiate an oncogenic role for FGFR3.
|
9787135 |
1998 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
|
9207791 |
1997 |